Latest News

A large multicenter study found that APOE genotype and a polygenic Alzheimer risk score together predict up to a 10-year difference in disease onset among people carrying an extra copy of the APP gene, whether through an APP duplication or Down syndrome.

Experimental small molecule CN045 promoted oligodendrocyte maturation and modest remyelination in preclinical models of multiple sclerosis, supporting further development of the compound as a potential remyelination therapy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 14, 2026.

Clinician author Kevin Chang, PharmD, writes about PACAP as a distinct, druggable migraine pathway independent of CGRP, offering a promising option for patients who don't respond to current therapies.

The FDA approved TAUKLARIFY (florquinitau F 18 injection), a tau PET imaging agent, for identifying tau neurofibrillary tangle pathology in adults being evaluated for Alzheimer disease.

Voyager Therapeutics is advancing 2 tau-targeted Alzheimer disease therapies toward key clinical milestones expected in the fourth quarter of 2026, including tau PET imaging data for VY7523 and first-in-human dosing for VY1706.

The FDA has cleared Quantum BioPharma's investigational new drug application for Lucid-MS, allowing the company to begin a phase 2 trial of the first-in-class demyelination-targeting compound in progressive multiple sclerosis.

Uma Menon, MD, Adult Neurology Residency Program Director at Allina Health, shares lessons on navigating fellowship, finding the right career path, building expertise, and maintaining balance throughout a career in neurology.

CurePSP and UCSF announced enrollment of the first participant in the PSP Trial Platform, believed to be the first platform trial ever conducted specifically for progressive supranuclear palsy, designed to test multiple investigational drugs simultaneously.

Ractigen Therapeutics announced completion of enrollment and first dosing across all cohorts of its phase 2 trial of RAG-17, an investigational siRNA therapy for SOD1-mutated ALS, building on phase 1 data recently published in Nature Medicine.

Senda Ajroud-Driss, MD, director of the ALS Clinic at Northwestern Medicine, discussed why adults with spinal muscular atrophy continue to need multidisciplinary care and where the evidence still falls short.

Divya Jayaraman, MD, PhD, a pediatric neuromuscular specialist at Columbia University Irving Medical Center, discussed the comparative evidence gaps in spinal muscular atrophy and the difficulty of moving patients into adult care.

Horacio Kaufmann, MD, Director of the Dysautonomia Center at NYU Langone, discusses the prospective validation of prodromal MSA criteria, how olfactory testing can sharpen specificity, and how close the field is to biomarker-driven early diagnosis.